# A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

> **NCT06329947** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Rui-hua Xu, MD, PhD** · enrollment: 37 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Surufatinib 250mg/d qd once daily

## Key facts

- **NCT ID:** NCT06329947
- **Lead sponsor:** Rui-hua Xu, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-22
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-09-30
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329947, "A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06329947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*